BioCentury
ARTICLE | Company News

Access Pharmaceuticals, Norgine deal

September 8, 2014 7:00 AM UTC

Access granted Norgine exclusive rights to develop and commercialize Access' MuGard for oral mucositis in the EU, Switzerland, Norway, Iceland and Lichtenstein. Access is eligible for up to $10 million in milestones, plus escalating double-digit royalties. Norgine is responsible for gaining regulatory approval of the mucoadhesive oral rinse, which it plans to launch in Europe next year. ...